Nucleix secures $55M in funding for lung cancer test

April 7, 2021 -- Liquid biopsy company Nucleix has secured $55 million to advance Lung EpiCheck, an early detection lung cancer test based on methylation technology.

Nucleix will use the financing to continue to advance its methylation technology and the blood-based assay. The test analyzes subtle, disease-specific changes in DNA methylation markers in patients, specifically current and former smokers.

Copyright © 2021

To read this and get access to all of the exclusive content on, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?